Article Sidebar
Date Published:
01/06/2023
Abstract Views: 253
Views PDF: 87
Views PDF: 87
Issue
Section
Các bài báo
How to Cite
Phùng , T. H. ., & Khúc , C. H. . (2023). RESULTS OF IRINOTECAN IN THE TREATMENT OF RECURRENT AND METASTATIC CERVICAL CANCER, IN K HOSPITAL. Vietnam Medical Journal, 526(2). https://doi.org/10.51298/vmj.v526i2.5580
RESULTS OF IRINOTECAN IN THE TREATMENT OF RECURRENT AND METASTATIC CERVICAL CANCER, IN K HOSPITAL
Main Article Content
Abstract
Objectives: Evaluation of Overall Response Rate and Side Effects in patients with recurrent and metastatic cervical cancer treated with paclitaxel carboplatin. Materials and methods: A retrospective and prospective descriptive study was conducted on 26 recurrent and metastatic cervical cancer patients received Irinotecan in K hospital. Results: The clinical benefits was 46,2%; complete response was 0%; partial response account 15,4%, stable disease was recorded as 30,8%. Conclusions: Paclitaxel carboplatin regimen is effective in recurrent endometrial cancer patients.
Article Details
Keywords
Recurrent cervical cancer patients, Irinotecan
References
1. Bray F, Ferlay J, Soerjomataram I, et al. Cervical cancer in young women in Taiwan: CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2. Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;71(3):209-249. doi:10.3322/caac.21660
3. Cao L, Li X, Zhang Y, Li X, Wang Q. Clinical features and prognosis of cervical cancer in young women. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010, 35(8):875-878.
4. NCCN (2022), Cervix Cancer NCCN clinical practice guidelines in oncology v.1.2022.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000), Cervical Cancer Incidence Among US Women, 2001-2019 J Natl Cancer Inst, 92(3), pp. 205-16.
6. Lhommé C., Fumoleau P., Fargeot P. và cộng sự. (1999). Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol, 17(10), 3136–3142.
7. Look K.Y., Blessing J.A., Levenback C. và cộng sự. (1998). A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol, 70(3), 334–338.
8. Verschraegen C.F. (2002). Irinotecan for the treatment of cervical cancer. Oncology (Williston Park), 16(5 Suppl 5), 32–34.
2. Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;71(3):209-249. doi:10.3322/caac.21660
3. Cao L, Li X, Zhang Y, Li X, Wang Q. Clinical features and prognosis of cervical cancer in young women. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010, 35(8):875-878.
4. NCCN (2022), Cervix Cancer NCCN clinical practice guidelines in oncology v.1.2022.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000), Cervical Cancer Incidence Among US Women, 2001-2019 J Natl Cancer Inst, 92(3), pp. 205-16.
6. Lhommé C., Fumoleau P., Fargeot P. và cộng sự. (1999). Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol, 17(10), 3136–3142.
7. Look K.Y., Blessing J.A., Levenback C. và cộng sự. (1998). A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol, 70(3), 334–338.
8. Verschraegen C.F. (2002). Irinotecan for the treatment of cervical cancer. Oncology (Williston Park), 16(5 Suppl 5), 32–34.